OGN
Organon & Co.
Price Chart
Latest Quote
$13.40
+0.01 (+0.04%)
Current Price
| Previous Close | $13.39 |
| Open | $13.42 |
| Day High | $13.41 |
| Day Low | $13.39 |
| Volume | 100,126 |
Stock Information
| Quarterly Dividend / Yield | $0.08 / 0.60% |
| Shares Outstanding | 262.61M |
| Quarterly Dividend Yield | 0.60% |
| Quarterly Dividend | $0.08 |
| Total Debt | $8.57B |
| Cash Equivalents | $1.12B |
| Revenue | $6.16B |
| Net Income | $246.00M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market Cap | $3.52B |
| P/E Ratio | 14.41 |
| EPS (TTM) | $0.93 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $10.97B |
| Sales | $6.16B |
| Income | $246.00M |
| Book/sh | $3.44 |
| Cash/sh | $4.25 |
| Employees | 10K |
Financial Ratios
| Quick Ratio | 1.00 |
| Current Ratio | 1.97 |
| Debt/Eq | 948.95 |
| EPS Growth TTM | 67.80% |
Returns & Margins
| ROA | 5.89% |
| ROE | 34.05% |
| Gross Margin | 53.84% |
| Operating Margin | 18.70% |
| Profit Margin | 3.99% |
Ownership
| Insider Ownership | 0.47% |
| Institutional Ownership | 77.93% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 3.66 |
| P/S | 0.57 |
| P/B | 3.90 |
Analyst Data
| Recommendation | none |
| Target Price | $11.25 |
Technical Indicators
| SMA20 | $13.40 |
| SMA50 | $12.54 |
| SMA200 | $9.10 |
| RSI | 53.85 |
| ATR | 0.0471 |
| Shares Float | 261.08M |
| Short Float | 7.82% |
| Short Ratio | 3.07 |
| Volatility | 1.54 |
| Rel Volume | 0.04 |
Performance History
| Week | -0.30% |
| Month | -0.15% |
| Quarter | +120.36% |
| 6 Months | +96.69% |
| YTD | +85.82% |
| Year | +38.65% |
| 3 Years | -27.28% |
| 5 Years | -48.31% |
| 10 Years | -50.55% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $13.40 | 100,126 |
| 2026-06-22 | $13.40 | 2,217,800 |
| 2026-06-18 | $13.43 | 5,074,600 |
| 2026-06-17 | $13.42 | 2,728,900 |
| 2026-06-16 | $13.42 | 2,589,900 |
| 2026-06-15 | $13.44 | 2,164,200 |
| 2026-06-12 | $13.44 | 1,815,500 |
| 2026-06-11 | $13.45 | 4,187,200 |
| 2026-06-10 | $13.38 | 1,692,900 |
| 2026-06-09 | $13.40 | 1,781,300 |
| 2026-06-08 | $13.39 | 2,758,900 |
| 2026-06-05 | $13.36 | 2,188,100 |
| 2026-06-04 | $13.40 | 1,326,100 |
| 2026-06-03 | $13.40 | 2,566,200 |
| 2026-06-02 | $13.38 | 2,567,600 |
| 2026-06-01 | $13.36 | 3,527,500 |
| 2026-05-29 | $13.34 | 5,416,900 |
| 2026-05-28 | $13.35 | 3,292,900 |
| 2026-05-27 | $13.38 | 3,388,600 |
| 2026-05-26 | $13.41 | 2,671,100 |
About Organon & Co.
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
đ° Latest News
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Zacks âĸ 2026-06-22T13:00:03Z
Is TOFIDENCEâs Expanded CRS and COVID Label Altering The Investment Case For Organon (OGN)?
Simply Wall St. âĸ 2026-06-16T00:17:31Z
Organon (OGN) Stock After New TOFIDENCE Approval A Fresh Look At Valuation And Recovery Potential
Simply Wall St. âĸ 2026-06-15T08:08:21Z
Organon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-19
Zacks âĸ 2026-06-12T13:15:00Z
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Zacks âĸ 2026-06-09T13:00:03Z
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Zacks âĸ 2026-05-29T13:00:04Z
Organon Audit Cleared And New Data Put Valuation And Risks In Focus
Simply Wall St. âĸ 2026-05-25T23:08:35Z
Indiaâs pharma industry is going global. But can it catch up to China?
Pharma Voice âĸ 2026-05-13T09:00:40Z
Organon Buyout By Sun Pharma Shifts Focus To Cash Value And Timing
Simply Wall St. âĸ 2026-05-07T12:12:05Z
Lilly, Gilead lead pharmaâs M&A boom
Pharma Voice âĸ 2026-05-07T08:52:25Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $2,903,000,000 | $2,688,000,000 | $2,515,000,000 | $2,294,000,000 |
| Cost Of Revenue | $2,903,000,000 | $2,688,000,000 | $2,515,000,000 | $2,294,000,000 |
| Total Revenue | $6,216,000,000 | $6,403,000,000 | $6,263,000,000 | $6,174,000,000 |
| Operating Revenue | $6,216,000,000 | $6,403,000,000 | $6,263,000,000 | $6,174,000,000 |
| Expenses | ||||
| Interest Expense | $504,000,000 | $520,000,000 | $527,000,000 | $422,000,000 |
| Total Expenses | $4,990,000,000 | $4,917,000,000 | $4,936,000,000 | $4,469,000,000 |
| Other Income Expense | $-297,000,000 | $-159,000,000 | $-127,000,000 | $-161,000,000 |
| Other Non Operating Income Expenses | $119,000,000 | $-21,000,000 | $-15,000,000 | $-15,000,000 |
| Net Non Operating Interest Income Expense | $-504,000,000 | $-520,000,000 | $-527,000,000 | $-422,000,000 |
| Interest Expense Non Operating | $504,000,000 | $520,000,000 | $527,000,000 | $422,000,000 |
| Operating Expense | $2,087,000,000 | $2,229,000,000 | $2,421,000,000 | $2,175,000,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $187,000,000 | $864,000,000 | $1,023,000,000 | $917,000,000 |
| Net Interest Income | $-504,000,000 | $-520,000,000 | $-527,000,000 | $-422,000,000 |
| Normalized Income | $515,640,000 | $973,020,000 | $1,111,480,000 | $1,036,282,000 |
| Net Income From Continuing And Discontinued Operation | $187,000,000 | $864,000,000 | $1,023,000,000 | $917,000,000 |
| Net Income Common Stockholders | $187,000,000 | $864,000,000 | $1,023,000,000 | $917,000,000 |
| Net Income | $187,000,000 | $864,000,000 | $1,023,000,000 | $917,000,000 |
| Net Income Including Noncontrolling Interests | $187,000,000 | $864,000,000 | $1,023,000,000 | $917,000,000 |
| Net Income Continuous Operations | $187,000,000 | $864,000,000 | $1,023,000,000 | $917,000,000 |
| Pretax Income | $425,000,000 | $807,000,000 | $673,000,000 | $1,122,000,000 |
| Special Income Charges | $-402,000,000 | $-112,000,000 | $-70,000,000 | $-135,000,000 |
| Operating Income | $1,226,000,000 | $1,486,000,000 | $1,327,000,000 | $1,705,000,000 |
| Gross Profit | $3,313,000,000 | $3,715,000,000 | $3,748,000,000 | $3,880,000,000 |
| Net Income Discontinuous Operations | - | - | $0 | $0 |
| Per Share | ||||
| Diluted EPS | $0.72 | $3.33 | $3.99 | $3.59 |
| Basic EPS | $0.72 | $3.36 | $4.01 | $3.61 |
| Other | ||||
| Tax Effect Of Unusual Items | $-87,360,000 | $-28,980,000 | $-23,520,000 | $-26,718,000 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $1,706,000,000 | $1,742,000,000 | $1,548,000,000 | $1,902,000,000 |
| Total Unusual Items | $-416,000,000 | $-138,000,000 | $-112,000,000 | $-146,000,000 |
| Total Unusual Items Excluding Goodwill | $-416,000,000 | $-138,000,000 | $-112,000,000 | $-146,000,000 |
| Reconciled Depreciation | $361,000,000 | $277,000,000 | $236,000,000 | $212,000,000 |
| EBITDA (Bullshit earnings) | $1,290,000,000 | $1,604,000,000 | $1,436,000,000 | $1,756,000,000 |
| EBIT | $929,000,000 | $1,327,000,000 | $1,200,000,000 | $1,544,000,000 |
| Diluted Average Shares | $260,764,000 | $259,152,000 | $256,270,000 | $255,169,000 |
| Basic Average Shares | $259,495,000 | $257,046,000 | $255,239,000 | $254,082,000 |
| Diluted NI Availto Com Stockholders | $187,000,000 | $864,000,000 | $1,023,000,000 | $917,000,000 |
| Tax Provision | $238,000,000 | $-57,000,000 | $-350,000,000 | $205,000,000 |
| Other Special Charges | $6,000,000 | $81,000,000 | $8,000,000 | $107,000,000 |
| Impairment Of Capital Assets | $301,000,000 | $0 | $0 | - |
| Restructuring And Mergern Acquisition | $95,000,000 | $31,000,000 | $62,000,000 | $28,000,000 |
| Gain On Sale Of Security | $-14,000,000 | $-26,000,000 | $-42,000,000 | $-11,000,000 |
| Research And Development | $366,000,000 | $469,000,000 | $528,000,000 | $471,000,000 |
| Selling General And Administration | $1,721,000,000 | $1,760,000,000 | $1,893,000,000 | $1,704,000,000 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-4,531,000,000 | $-5,622,000,000 | $-5,206,000,000 | $-6,144,000,000 |
| Total Assets | $12,867,000,000 | $13,101,000,000 | $12,058,000,000 | $10,955,000,000 |
| Total Non Current Assets | $8,515,000,000 | $8,753,000,000 | $7,550,000,000 | $7,024,000,000 |
| Other Non Current Assets | $1,929,000,000 | $1,491,000,000 | $1,231,000,000 | $754,000,000 |
| Goodwill And Other Intangible Assets | $5,283,000,000 | $6,094,000,000 | $5,136,000,000 | $5,252,000,000 |
| Other Intangible Assets | $1,130,000,000 | $1,414,000,000 | $533,000,000 | $649,000,000 |
| Current Assets | $4,352,000,000 | $4,348,000,000 | $4,508,000,000 | $3,931,000,000 |
| Other Current Assets | $1,033,000,000 | $994,000,000 | $756,000,000 | $747,000,000 |
| Assets Held For Sale Current | $8,000,000 | $0 | - | - |
| Inventory | $1,406,000,000 | $1,321,000,000 | $1,315,000,000 | $1,003,000,000 |
| Receivables | $1,331,000,000 | $1,358,000,000 | $1,744,000,000 | $1,475,000,000 |
| Accounts Receivable | $1,331,000,000 | $1,358,000,000 | $1,744,000,000 | $1,475,000,000 |
| Allowance For Doubtful Accounts Receivable | $-12,000,000 | $-14,000,000 | $-9,000,000 | $-9,000,000 |
| Gross Accounts Receivable | $1,343,000,000 | $1,372,000,000 | $1,753,000,000 | $1,484,000,000 |
| Cash Cash Equivalents And Short Term Investments | $574,000,000 | $675,000,000 | $693,000,000 | $706,000,000 |
| Cash And Cash Equivalents | $574,000,000 | $675,000,000 | $693,000,000 | $706,000,000 |
| Debt | ||||
| Net Debt | $8,070,000,000 | $8,205,000,000 | $8,067,000,000 | $8,207,000,000 |
| Total Debt | $8,644,000,000 | $8,880,000,000 | $8,760,000,000 | $8,913,000,000 |
| Long Term Debt And Capital Lease Obligation | $8,628,000,000 | $8,860,000,000 | $8,751,000,000 | $8,905,000,000 |
| Long Term Debt | $8,628,000,000 | $8,860,000,000 | $8,751,000,000 | $8,905,000,000 |
| Current Debt And Capital Lease Obligation | $16,000,000 | $20,000,000 | $9,000,000 | $8,000,000 |
| Current Debt | $16,000,000 | $20,000,000 | $9,000,000 | $8,000,000 |
| Other Current Borrowings | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $12,115,000,000 | $12,629,000,000 | $12,128,000,000 | $11,847,000,000 |
| Total Non Current Liabilities Net Minority Interest | $9,725,000,000 | $9,911,000,000 | $9,210,000,000 | $9,335,000,000 |
| Other Non Current Liabilities | $1,008,000,000 | $977,000,000 | $412,000,000 | $411,000,000 |
| Liabilities Heldfor Sale Non Current | $32,000,000 | $0 | - | - |
| Non Current Deferred Liabilities | $57,000,000 | $74,000,000 | $47,000,000 | $19,000,000 |
| Non Current Deferred Taxes Liabilities | $57,000,000 | $74,000,000 | $47,000,000 | $19,000,000 |
| Current Liabilities | $2,390,000,000 | $2,718,000,000 | $2,918,000,000 | $2,512,000,000 |
| Other Current Liabilities | $2,000,000 | - | - | $1,188,000,000 |
| Payables And Accrued Expenses | $2,372,000,000 | $2,698,000,000 | $2,909,000,000 | $2,504,000,000 |
| Payables | $1,037,000,000 | $1,287,000,000 | $1,520,000,000 | $1,316,000,000 |
| Total Tax Payable | $85,000,000 | $134,000,000 | $206,000,000 | $184,000,000 |
| Income Tax Payable | $85,000,000 | $134,000,000 | $206,000,000 | $184,000,000 |
| Accounts Payable | $952,000,000 | $1,153,000,000 | $1,314,000,000 | $1,132,000,000 |
| Equity | ||||
| Common Stock Equity | $752,000,000 | $472,000,000 | $-70,000,000 | $-892,000,000 |
| Total Equity Gross Minority Interest | $752,000,000 | $472,000,000 | $-70,000,000 | $-892,000,000 |
| Stockholders Equity | $752,000,000 | $472,000,000 | $-70,000,000 | $-892,000,000 |
| Gains Losses Not Affecting Retained Earnings | $-527,000,000 | $-649,000,000 | $-541,000,000 | $-564,000,000 |
| Other Equity Adjustments | $-527,000,000 | $-649,000,000 | $-541,000,000 | $-564,000,000 |
| Retained Earnings | $1,109,000,000 | $1,010,000,000 | $443,000,000 | $-331,000,000 |
| Other | ||||
| Ordinary Shares Number | $260,316,000 | $257,799,000 | $255,626,000 | $254,370,000 |
| Share Issued | $260,316,000 | $257,799,000 | $255,626,000 | $254,370,000 |
| Tangible Book Value | $-4,531,000,000 | $-5,622,000,000 | $-5,206,000,000 | $-6,144,000,000 |
| Invested Capital | $9,396,000,000 | $9,352,000,000 | $8,690,000,000 | $8,021,000,000 |
| Working Capital | $1,962,000,000 | $1,630,000,000 | $1,590,000,000 | $1,419,000,000 |
| Total Capitalization | $9,380,000,000 | $9,332,000,000 | $8,681,000,000 | $8,013,000,000 |
| Additional Paid In Capital | $167,000,000 | $108,000,000 | $25,000,000 | $0 |
| Capital Stock | $3,000,000 | $3,000,000 | $3,000,000 | $3,000,000 |
| Common Stock | $3,000,000 | $3,000,000 | $3,000,000 | $3,000,000 |
| Current Accrued Expenses | $1,335,000,000 | $1,411,000,000 | $1,389,000,000 | $1,188,000,000 |
| Goodwill | $4,153,000,000 | $4,680,000,000 | $4,603,000,000 | $4,603,000,000 |
| Net PPE | $1,303,000,000 | $1,168,000,000 | $1,183,000,000 | $1,018,000,000 |
| Accumulated Depreciation | $-1,239,000,000 | $-1,060,000,000 | $-1,017,000,000 | $-902,000,000 |
| Gross PPE | $2,542,000,000 | $2,228,000,000 | $2,200,000,000 | $1,920,000,000 |
| Construction In Progress | $289,000,000 | $286,000,000 | $274,000,000 | $278,000,000 |
| Machinery Furniture Equipment | $1,388,000,000 | $1,209,000,000 | $1,191,000,000 | $935,000,000 |
| Buildings And Improvements | $850,000,000 | $721,000,000 | $721,000,000 | $694,000,000 |
| Land And Improvements | $15,000,000 | $12,000,000 | $14,000,000 | $13,000,000 |
| Properties | $0 | $0 | $0 | $0 |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $384,000,000 | $588,000,000 | $538,000,000 | $431,000,000 |
| Operating Activities | ||||
| Operating Cash Flow | $700,000,000 | $939,000,000 | $799,000,000 | $858,000,000 |
| Cash Flow From Continuing Operating Activities | $700,000,000 | $939,000,000 | $799,000,000 | $858,000,000 |
| Operating Gains Losses | $-94,000,000 | $-2,000,000 | $40,000,000 | $-18,000,000 |
| Cash From Discontinued Operating Activities | - | - | $0 | $0 |
| Investing Activities | ||||
| Capital Expenditure | $-316,000,000 | $-351,000,000 | $-261,000,000 | $-427,000,000 |
| Investing Cash Flow | $-390,000,000 | $-513,000,000 | $-260,000,000 | $-420,000,000 |
| Cash Flow From Continuing Investing Activities | $-390,000,000 | $-513,000,000 | $-260,000,000 | $-420,000,000 |
| Capital Expenditure Reported | $-162,000,000 | $-175,000,000 | $-251,000,000 | $-196,000,000 |
| Cash From Discontinued Investing Activities | - | - | $0 | $0 |
| Financing Activities | ||||
| Financing Cash Flow | $-561,000,000 | $-368,000,000 | $-569,000,000 | $-433,000,000 |
| Cash Flow From Continuing Financing Activities | $-561,000,000 | $-368,000,000 | $-569,000,000 | $-433,000,000 |
| Net Other Financing Charges | $-15,000,000 | $-60,000,000 | $-17,000,000 | $-35,000,000 |
| Cash Dividends Paid | $-88,000,000 | $-297,000,000 | $-294,000,000 | $-290,000,000 |
| Common Stock Dividend Paid | $-88,000,000 | $-297,000,000 | $-294,000,000 | $-290,000,000 |
| Cash From Discontinued Financing Activities | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-1,513,000,000 | $-1,197,000,000 | $-338,000,000 | $-108,000,000 |
| Issuance Of Debt | $1,055,000,000 | $1,186,000,000 | $80,000,000 | $0 |
| End Cash Position | $574,000,000 | $675,000,000 | $693,000,000 | $706,000,000 |
| Beginning Cash Position | $675,000,000 | $693,000,000 | $706,000,000 | $737,000,000 |
| Effect Of Exchange Rate Changes | $150,000,000 | $-76,000,000 | $17,000,000 | $-36,000,000 |
| Changes In Cash | $-251,000,000 | $58,000,000 | $-30,000,000 | $5,000,000 |
| Net Issuance Payments Of Debt | $-458,000,000 | $-11,000,000 | $-258,000,000 | $-108,000,000 |
| Net Long Term Debt Issuance | $-458,000,000 | $-11,000,000 | $-258,000,000 | $-108,000,000 |
| Long Term Debt Payments | $-1,513,000,000 | $-1,197,000,000 | $-338,000,000 | $-108,000,000 |
| Long Term Debt Issuance | $1,055,000,000 | $1,186,000,000 | $80,000,000 | $0 |
| Net Business Purchase And Sale | $-75,000,000 | $-166,000,000 | $0 | $0 |
| Purchase Of Business | $-75,000,000 | $-166,000,000 | $0 | $0 |
| Net Intangibles Purchase And Sale | $-154,000,000 | $-176,000,000 | $-10,000,000 | $-231,000,000 |
| Purchase Of Intangibles | $-154,000,000 | $-176,000,000 | $-10,000,000 | $-231,000,000 |
| Net PPE Purchase And Sale | $1,000,000 | $4,000,000 | $1,000,000 | $7,000,000 |
| Sale Of PPE | $1,000,000 | $4,000,000 | $1,000,000 | $7,000,000 |
| Change In Working Capital | $-247,000,000 | $-278,000,000 | $-155,000,000 | $-452,000,000 |
| Change In Other Working Capital | $139,000,000 | $29,000,000 | $16,000,000 | $-8,000,000 |
| Change In Other Current Assets | $-32,000,000 | $-236,000,000 | $-10,000,000 | $-43,000,000 |
| Change In Payables And Accrued Expense | $-420,000,000 | $-323,000,000 | $281,000,000 | $-58,000,000 |
| Change In Accrued Expense | $-142,000,000 | $-101,000,000 | $102,000,000 | $172,000,000 |
| Change In Payable | $-278,000,000 | $-222,000,000 | $179,000,000 | $-230,000,000 |
| Change In Account Payable | $-217,000,000 | $-157,000,000 | $163,000,000 | $-237,000,000 |
| Change In Tax Payable | $-61,000,000 | $-65,000,000 | $16,000,000 | $7,000,000 |
| Change In Income Tax Payable | $-61,000,000 | $-65,000,000 | $16,000,000 | $7,000,000 |
| Change In Inventory | $-13,000,000 | $-131,000,000 | $-230,000,000 | $-220,000,000 |
| Change In Receivables | $79,000,000 | $383,000,000 | $-212,000,000 | $-123,000,000 |
| Changes In Account Receivables | $79,000,000 | $383,000,000 | $-212,000,000 | $-123,000,000 |
| Other Non Cash Items | $43,000,000 | $133,000,000 | $39,000,000 | $133,000,000 |
| Stock Based Compensation | $77,000,000 | $105,000,000 | $101,000,000 | $75,000,000 |
| Asset Impairment Charge | $310,000,000 | $0 | $0 | $9,000,000 |
| Deferred Tax | $63,000,000 | $-160,000,000 | $-485,000,000 | $-18,000,000 |
| Deferred Income Tax | $63,000,000 | $-160,000,000 | $-485,000,000 | $-18,000,000 |
| Depreciation Amortization Depletion | $361,000,000 | $277,000,000 | $236,000,000 | $212,000,000 |
| Depreciation And Amortization | $361,000,000 | $277,000,000 | $236,000,000 | $212,000,000 |
| Amortization Cash Flow | $205,000,000 | $145,000,000 | $116,000,000 | $116,000,000 |
| Amortization Of Intangibles | $205,000,000 | $145,000,000 | $116,000,000 | $116,000,000 |
| Depreciation | $156,000,000 | $132,000,000 | $120,000,000 | $96,000,000 |
| Net Foreign Currency Exchange Gain Loss | $-21,000,000 | $-2,000,000 | $40,000,000 | $-18,000,000 |
| Net Income From Continuing Operations | $187,000,000 | $864,000,000 | $1,023,000,000 | $917,000,000 |
| Other Cash Adjustment Outside Changein Cash | - | - | $0 | $0 |
| Net Short Term Debt Issuance | - | - | $0 | $0 |
| Short Term Debt Payments | - | - | $0 | $0 |
| Short Term Debt Issuance | - | - | - | $0 |
Fetched: 2026-06-23